EI-001 is under clinical development by Elixiron Immunotherapeutics and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase I drugs for Hemophagocytic Lymphohistiocytosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EI-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EI-001 overview

EI-001 is under development for the treatment of Vitiligo and hemophagocytic lymphohistiocytosis. It is administered through intravenous route. It was also under development for the treatment of chronic hepatitis B infection. It acts by targeting interferon gamma (IFN-gamma)

Elixiron Immunotherapeutics overview

Elixiron Immunotherapeutics (Elixiron) is a clinical stage company which advances in translational medicine to identify targets from clinical observations, and various drug modalities from a proprietary single human B cell cloning platform to develop

For a complete picture of EI-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.